Thursday, January 23, 2014
Publication and contact
prostate cancer (CRPC)
tissue studies suggest a combination of Src and MEK family
inhibitors could be useful for treating metastatic CRPC. Proteomic analysis
of phosphoproteins from 41 CRPC metastases in 17 patients identified patterns
of phosphorylation across multiple metastatic lesions from individual
patients. In a subset of 16 metastatic lesions, kinase activation predicted sensitivity
to combined Src and MEK family inhibition in about 69% of patients. Next
steps could include clinical testing of a combination of Src and MEK
plc and Japan
Tobacco Inc. market the MAP kinase
kinase 1 (MAP2K1;
At least six other MEK inhibitors are in Phase II or
Phase III testing for various cancers.
Squibb Co. and Otsuka
Pharmaceutical Co. Ltd.'s Sprycel
which inhibit Src as well as BCR-ABL
tyrosine kinase, are marketed for hematological
At least four other kinase inhibitors targeting Src are in Phase I and Phase
II testing for various cancers.
Published online Jan. 23, 2014
Patent and licensing status
Drake, J.M. et al. Proc.
Natl. Acad. Sci. USA; published online Nov. 18, 2013;
Contact: Owen N. Witte, University of California, Los
All contents Copyright © 1993-2016 BioCentury Publications, Inc. ALL RIGHTS RESERVED. All use of this Web Site and its contents is governed by the BioCentury User Agreement
. The contents of this Web Site are protected under U.S. and foreign copyright and intellectual property laws, and no part of this Web Site or its contents may be photocopied, reproduced or retransmitted in any form without the written consent of BioCentury, which may be requested from Reprints/Permissions
. BioCentury®; The Bernstein Report on BioBusiness™; The BioCentury 100™; The Clear Route to ROI™; Because Real Intelligence is Hard to Find™; BCIQ™; and BioPharma's Knowledge Center™; are trademarks of BioCentury Publications, Inc., P.O. Box 1246, San Carlos, CA 94070. SciBX® and SciBX: Science-Business eXchange® are trademarks of Nature America, Inc. that are jointly used by BioCentury Publications, Inc. and Nature America, Inc.
Thanks for purchasing this article.
Please bookmark this url for future reference.
We have also sent you a confirming e-mail with a receipt and this same url for your
close [ X ]